Abstract
The clinical efficacy, safety and usefulness of biapenem (BIPM), a new carbapenem antibiotic for injection, were evaluated in bacterial pneumonia in a comparative study with imipenem/cilastatin (IPM/CS). Patients were given 600 mg (potency) of BIPM or 1,000 mg (potency)/1,000 mg of IPM/CS daily (b.i.d.) for 14 days, and the following results were obtained: 1. A total of 183 cases were enrolled in this study, and 146 cases were evaluated for clinical efficacy. Efficacy rates were 94.8% (73/77) in the BIPM group and 92.8% (64/69) in the IPM/CS group, with no significant difference between the two groups. 2. Bacteriological eradication rates were 90.9% (20/22) in the BIPM group and 93.1% (27/29) in the IPM/CS group, with no significant difference between the two groups. 3. The incidence of adverse reaction was 3.4% (2/89) in the BIPM group and 3.6% (3/83) in the IPM/CS group. There was no significant difference between the two groups. The incidence of abnormal laboratory findings was 29.5% (26/88) in the BIPM group and 25.6% (20/78) in the IPM/CS group. There was no significant difference between the two groups. 4. The usefulness rates were 94.8% (73/77) in the BIPM group and 88.6% (62/70) in the IPM/CS group. There was no significant difference between the two groups. No significant differences were observed between 600 mg (potency) of BIPM and 1,000 mg (potency)/1,000 mg of IPM/CS daily (b.i.d.) with respect to any of the above parameters. These results indicate that BIPM is useful for the treatment of bacterial pneumonia and lung abscess.
Original language | English |
---|---|
Pages (from-to) | 41-62 |
Number of pages | 22 |
Journal | Japanese Journal of Chemotherapy |
Volume | 43 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1995 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)